Member Info for Sangijuelas1

I guess I am just a bit miffed that 14% of the company is being sold for 14m along with another 23m in warrants on top of the 22m warrants from the March placing.

Time will tell who sticks around

And been long since 2017

The fact that you don't know Bryan Garnier is a company broker says a lot also

Maybe read the posts. I am very long 4D and hoping the Longevity money does not turn out to be a Trojan horse for UK shareholders.
It is hard to find info on our fellow shareholder Mr Oliveira. There was a negative article on him but probably written by a short seller.
However, he made reference to reverse takeovers of Chinese companies through the SPAC method. We are merging with a SPAC. 4D are dealing with some hardened operators and I just hope that the board considers the interests of long term UK shareholders. If they read through any of the stuff written by mugs on here I am sure they would think stuff em. They are the reason we have to seek US capital in the 1st place.
I mean look at the Woodford debacle. People invested in a fund called Patient Capital and 5 minutes later expected to see a tripling of their investment.

Bryan Garnier is not independent. They are co brokers

You are right, it's only about another 1%

Yeah that's a start up in the biotech world.

Oliveira owns 7% of Longevity so will end up with over 20% of the company.

If they are nervous maybe they should not be invested in an extremely volatile biotech startup

The SPAC idea will have come from Oliveira and Chardan.

It's not a merger, it's a reverse takeover.

Because you are interested in getting the price to 107 so you can sell up.

I am interested in not having the company stolen by the Yanks

Chardan did the bookbuild for the July fundraising where Oliveira took a bigger chunk

https://buyersstrike.wordpress.com/2011/03/07/and-the-repros-therapeutics-grand-prizes-go-to-rprx/
Another big holder in RPRX, through the offering, with 7.38%, is Steven Oliveira. Steve keeps a fairly low profile, but he is well known to fans of Chinese reverse merger stocks. According to his bio from the China Broadband Inc. (CBBD) filings, Steve is part of the Chardan crew, a shop responsible for foisting a ton of SPACs onto the market. SPACs that more often than not did reverse mergers with junk Chinese companies that either could not do a proper IPO or did not want the scrutiny that comes from one. More interestingly, Steve learned the bio-dreck trade at none other than D. Blech & Co.

“On November 29, 2010, the Board of Directors of the Company appointed Steven Oliveira as a members of the Board of Directors of the Company. Mr. Oliveira has been Chief Investment Officer of Chardan SPAC Asset Management, LLC since 2008, and President of Oliveira Capital, LLC since its inception in 2002, with a focus on investments in Asia, biotechnology and Special Purpose Acquisition Companies. In 1995, while a Managing Partner at CSO Ventures, Mr. Oliveira co-founded DepoMed, Inc. and Siga Pharmaceuticals, Inc. Mr. Oliveira’s career in biotechnology began in 1992 as a Vice President at D. Blech and Company, an investment bank that specialized in financing emerging companies in the life sciences sector.”

Looking into it a bit more has actually put my mind at rest

As I said I am probably getting ahead of myself. Verona listed on Nasdaq in 2017 and Mereo in 2018 so maybe not an immediate concern.

This is not about talking down the company. It's about what is in the best long term interest of UK shareholders.

Neither were Verona. Them and Mereo decided to cancel the Aim shares once Nasdaq volume was up. Said the dual listing was too costly

https://www.lse.co.uk/ShareChat.asp?ShareTicker=VRP&share=Verona-Pharma-Plc

https://www.lse.co.uk/ShareChat.asp?ShareTicker=VRP&share=Verona-Pharma-Plc